CD274 and diabetes mellitus: However, analysis of 9 phase 3 clinical trials comprising 3447 eligible patients to assess the efficacy and safety of durvalumab, another selective, high-affinity PD-L1 inhibitor, revealed that a total of 9 (0.26%) patients were diagnosed as ICI-DM, which was statistically lower than that induced by Atezolizumab (P=0.001).